BioSight
Back
Sarepta Therapeutics, Inc. logo

SRPT

NASDAQCAMBRIDGE, MA
Sarepta Therapeutics, Inc.

Sarepta Therapeutics develops treatments using proprietary technology platforms including phosphorodiamidate morpholino oligomers (PMO), gene therapy, and small interfering RNA (siRNA) to address a broad range of diseases. The company has marketed products for muscular dystrophy and other conditions, while maintaining a pipeline of clinical and development-stage candidates supported by manufacturing partnerships. Sarepta faced a clinical hold on gene therapy trials for limb-girdle muscular dystrophy in July 2025 and is conducting a confirmatory trial for two of its marketed products.

$20.88-66.54%1Y
SRPT · daily close · illustrative · 0 catalysts marked
1Y high$63.661Y low$11.93range$51.73(434%)past catalysts

Pipeline3

Eteplirsen
Phase 3Muscular Dystrophy, Duchenne

Eteplirsen is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping.

small-molecule
Glucocorticoid
Phase 3Limb-girdle Muscular Dystrophy
small-molecule
SRP-9003
Phase 3Limb-girdle Muscular Dystrophy
small-molecule

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.